A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading ...
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish... Janus Henderson Investors, an investment management company, released its “Janus ...
The average one-year price target for NeoGenomics (NasdaqCM:NEO) has been revised to $12.44 / share. This is an increase of ...
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below ...
Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, ...
Investing.com -- Shares of Neo Performance Materials Inc (TSX:NEO) climbed 7.1% following the announcement of a Normal Course Issuer Bid (NCIB) and the commencement of trading on the OTCQX market. The ...
NEO is a TSX stock that has more than doubled over the last 12 months. Here’s why it can continue to outperform. Valued at $700 million, Neo Performance Materials specializes in rare earth materials ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback